Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway

Amniotic mesenchymal stem cells attenuate diabetic cardiomyopathy by inhibiting pyroptosis via modulation of the TLR4/NF-κb/NLRP3 pathway

Diabetic cardiomyopathy (DCM) is a specific type of cardiac dysfunction in diabetic patients, currently has no effective therapies. The TLR4 signaling pathway, activated through MyD88 and NF-κB, plays a critical role in DCM by triggering the release of pro-inflammatory cytokines and promoting pyropt...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuan Zhou, Shaoliang Xing, Lina Zhang, Jungu Lu, Deming Li, Yating Wang, Yuhang Ma, Weiqin Chang, Manman Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
diabetic cardiomyopathy
type 2 diabetes mellitus
amniotic mesenchymal stem cells
fibrosis
pyroptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1631973/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic cardiomyopathy (DCM) is a specific type of cardiac dysfunction in diabetic patients, currently has no effective therapies. The TLR4 signaling pathway, activated through MyD88 and NF-κB, plays a critical role in DCM by triggering the release of pro-inflammatory cytokines and promoting pyroptosis through NLRP3 inflammasomes. Additionally, the TGF-β/Smad signaling pathway drives myocardial fibrosis, further compromising cardiac function. Recently, amniotic mesenchymal stem cells (AMSCs) have emerged as a promising therapeutic option due to their ease of access, low immunogenicity, and ability to differentiate into multiple cell types. In this study, a DCM mouse model was treated with AMSCs via tail vein injection every 2 weeks for four doses. Evaluations included glucose tolerance tests, echocardiography, serum analysis, and histopathological and molecular assessments. Results showed AMSCs improved pancreatic function, reduced blood glucose, and enhanced insulin secretion. Cardiac function and morphology improved, with reduced inflammation. Molecularly, AMSCs inhibited pyroptosis via TLR4/NF-κB/NLRP3 pathway suppression and reduced fibrosis through TGF-β/Smad modulation. These findings indicate AMSCs alleviate DCM cardiac dysfunction and pyroptosis, primarily by inhibiting the TLR4/NF-κB/NLRP3 pathway. The study underscores AMSCs as a promising therapeutic strategy for DCM, warranting further clinical exploration.
ISSN:2296-634X

Similar Items